在癌症治疗中向蛋白质溶解的嵌合体:针对下一代治疗的向蛋白质降解
Yamile Abuchard Anaya1,2, Mariana Barragan1,2, Ricardo Pequeno Bracho1,2,3
1Division of Cancer Immunology and Microbiology, Medicine, and Oncology Integrated Service Unit, School of Medicine, The University of Texas Rio Grande Valley, McAllen, Texas, USA.
Cancer
|October 18, 2025
概括
化向化体 (PROTACs) 通过降解致病蛋白质,为癌症治疗提供了一种新的方法. 这种方法有望为各种癌症提供更有效,更少毒性的治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 向蛋白解酶的仿真体 (PROTACs) 利用无素-蛋白酶体系统进行向蛋白质降解.
- PROTACs提供了一种新的策略,用于向以前被认为是常规抑制剂无法治疗的蛋白质.
研究的目的:
- 提供PROTAC开发,机制和癌症治疗中的临床应用的全面审查.
- 突出PROTACs在克服耐药性和推进个性化癌症治疗方面的潜力.
主要方法:
- 对PROTAC技术,作用机制和临床前/临床研究的现有文献的审查.
- 分析PROTAC设计原则,包括双功能分子结构和E3结合酶招募.
主要成果:
- 在治疗固体和血液性恶性瘤方面,PROTACs表现有前途,临床试验中有几个候选药物.
- 与抑制剂相比,PROTACs的催化降解会导致持续的目标抑制,剂量可能更低,毒性降低.
结论:
- 由于其模块化和精确性,PROTACs代表了个性化癌症治疗的有希望的下一代平台.
- 优化PROTAC的挑战包括药理动力学,E3结合酶选择和瘤输送,这需要进一步研究.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Proteasome
10.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K
Regulated Protein Degradation
3.1K
3.1K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


